In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection

References

• Garcia-Vidal E, Badia R, Pujantell M, et al. Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. Antiviral Res. 2019;168:18–27. doi:10.1016/j.antiviral.2019.05.003
   PubMedGoogle Scholar
• Gama L, Koup RA. New-generation high-potency and designer antibodies: role in HIV-1 treatment. Annu Rev Med. 2018;69:409–419.
   PubMedGoogle Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132.
   PubMed Web of Science ®Google Scholar
• Boonstra H, Barot S, Lusti-Narasimhan M. Making the case for multipurpose prevention technologies: the socio-epidemiological rationale. BJOG. 2014;121 Suppl 5:23–26. doi:10.1111/1471-0528.12851
   PubMedGoogle Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830–839.
   PubMed Web of Science ®Google Scholar
• Rupp R, Rosenthal SL, Stanberry LR. VivaGel(™) (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine. 2007;2:561–566.
   PubMed Web of Science ®Google Scholar
• Prokofjeva MM, Kochetkov SN, Prassolov VS. Therapy of HIV infection: current approaches and prospects. Acta Naturae. 2016;8:23–32.
   PubMedGoogle Scholar
• Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85:1–18.
   PubMed Web of Science ®Google Scholar
• Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2:a007161.
   PubMed Web of Science ®Google Scholar
• Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48(7):931–939. doi:10.1086/597290
   PubMed Web of Science ®Google Scholar
• Mamo T, Moseman EA, Kolishetti N, et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine. 2010;5(2):269–285. doi:10.2217/nnm.10.1
   PubMed Web of Science ®Google Scholar
• Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317(4):192–197. doi:10.1056/NEJM198707233170402
   PubMed Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.. Antivir Ther. 2005;10(6):727.
   PubMed Web of Science ®Google Scholar
• Ferir G, Palmer KE, Schols D. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology. 2011;417(2):253–258. doi:10.1016/j.virol.2011.07.004
   PubMedGoogle Scholar
• Chupradit K, Moonmuang S, Nangola S, et al. Current peptide and protein candidates challenging HIV therapy beyond the vaccine era. Viruses. 2017;9(10):281. doi:10.3390/v9100281
   PubMedGoogle Scholar
• Mitchell CA, Ramessar K, O’Keefe BR. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 2017;142:37–54.
   PubMed Web of Science ®Google Scholar
• Baker MP, Carr FJ. Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics. Curr Drug Saf. 2010;5:308–313.
   PubMedGoogle Scholar
• Mori T, O’Keefe BR, Sowder RC 2nd, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 2005;280:9345–9353. doi:10.1074/jbc.M411122200
   PubMed Web of Science ®Google Scholar
• Emau P, Tian B, O’keefe B, et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti‐HIV microbicide. J Med Primatol. 2007;36:244–253.
   PubMed Web of Science ®Google Scholar
• O’Keefe BR, Giomarelli B, Barnard DL, et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 2010;84:2511–2521. doi:10.1128/JVI.02322-09
   PubMed Web of Science ®Google Scholar
• O’Keefe BR, Vojdani F, Buffa V, et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A. 2009;106:6099–6104. doi:10.1073/pnas.0901506106
   PubMed Web of Science ®Google Scholar
• Barton C, Kouokam JC, Lasnik AB, et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58:120–127. doi:10.1128/AAC.01407-13
   PubMed Web of Science ®Google Scholar
• Kouokam JC, Huskens D, Schols D, et al. Investigation of griffithsin’s interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One. 2011;6(e22635). doi:10.1371/journal.pone.0022635
   PubMedGoogle Scholar
• Günaydın G, Edfeldt G, Garber DA, et al. Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: in situ analyses of epithelial and immune cell markers in rectal mucosa. Sci Rep. 2019;9:1–12.
   PubMedGoogle Scholar
• Corman JM, Hamorsky KT, Shepherd JW, Hiatt E, Fuqua JL, Palmer KE. Stability of plasmid and viral banks supporting the cGMP manufacture of Q-Griffithsin from a TMV-based viral vector. J Biotechnol. 2020;320:74–76.
   PubMedGoogle Scholar
• Jiang Y, Cao S, Bright DK, et al. Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell–cell HIV transmission. Mol Pharm. 2015;12:4363–4374.
   PubMedGoogle Scholar
• Feng JY, Ly JK, Myrick F, et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology. 2009;6:44.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled Phase 3 trial. The Lancet. 2013;381:2083–2090.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599.
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518.
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–434.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–422.
   PubMed Web of Science ®Google Scholar
• Haberer JE. Current Concepts for PrEP Adherence: in The PrEP revolution; from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11:10.
   PubMed Web of Science ®Google Scholar
• Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J. 2009;11:78. doi:10.1208/s12248-009-9082-7
   PubMed Web of Science ®Google Scholar
• Guthrie KM, Vargas S, Shaw JG, et al. The promise of intravaginal rings for prevention: user perceptions of biomechanical properties and implications for prevention product development. PLoS One. 2015;10:e0145642.
   PubMedGoogle Scholar
• Emau P, Tian B, O’Keefe B, et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol. 2007;36:244–253. doi:10.1111/j.1600-0684.2007.00242.x
   PubMed Web of Science ®Google Scholar
• Nixon B, Stefanidou M, Mesquita PM, et al. Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J Virol. 2013;87:6257–6269. doi:10.1128/JVI.00012-13
   PubMedGoogle Scholar
• Steinbach JM. Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs. Cell Mol Life Sci. 2015;72:469–503. doi:10.1007/s00018-014-1756-3
   PubMed Web of Science ®Google Scholar
• Steinbach JM, Seo YE, Saltzman WM. Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater. 2015. doi:10.1016/j.actbio.2015.11.029
   PubMedGoogle Scholar
• Steinbach JM, Weller CE, Booth CJ, Saltzman WM. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release. 2012;162:102–110. doi:10.1016/j.jconrel.2012.06.008
   PubMed Web of Science ®Google Scholar
• Aniagyei SE, Sims LB, Malik DA, et al. Evaluation of poly(lactic-co-glycolic acid) and poly(dl-lactide-co-epsilon-caprolactone) electrospun fibers for the treatment of HSV-2 infection. Mater Sci Eng C Mater Biol Appl. 2017;72:238–251. doi:10.1016/j.msec.2016.11.029
   PubMedGoogle Scholar
• Ball C, Krogstad E, Chaowanachan T, Woodrow KA. Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One. 2012;7:e49792. doi:10.1371/journal.pone.0049792
   PubMed Web of Science ®Google Scholar
• Blakney AK, Ball C, Krogstad EA, Woodrow KA. Electrospun fibers for vaginal anti-HIV drug delivery. Antiviral Res. 2013;100 Suppl:S9–16. doi:10.1016/j.antiviral.2013.09.022
   PubMedGoogle Scholar
• Duan JH, Steinbach-Rankins JM. Adaptable Griffithsin delivery from polymer blend nanoparticles and electrospun fibers. Aids Res Hum Retrov. 2016;32:218.
   Google Scholar
• Ensign LM, Tang BC, Wang YY, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4:138ra179. doi:10.1126/scitranslmed.3003453
   Google Scholar
• Grooms TN, Vuong HR, Tyo KM, et al. Griffithsin-modified electrospun fibers as a delivery scaffold to prevent HIV infection. Antimicrob Agents Ch. 2016;60:6518–6531. doi:10.1128/Aac.00956-16
   PubMedGoogle Scholar
• Huang C, Soenen SJ, Rejman J, et al. Stimuli-responsive electrospun fibers and their applications. Chem Soc Rev. 2011;40:2417–2434. doi:10.1039/c0cs00181c
   PubMed Web of Science ®Google Scholar
• Huang C, Soenen SJ, van Gulck E, et al. Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery. Biomaterials. 2012;33:962–969. doi:10.1016/j.biomaterials.2011.10.004
   PubMed Web of Science ®Google Scholar
• Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2010;7:37–48. doi:10.1517/17425240903338055
   PubMed Web of Science ®Google Scholar
• Tyo KM, Steinbach-Rankins JM. Electrospun polymer nanofibers for long-term protection against HIV and HSV-2. Aids Res Hum Retrov. 2016;32:223.
   Google Scholar
• Wheeler LA, Trifonova R, Vrbanac V, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest. 2011;121:2401–2412. doi:10.1172/JCI45876
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater. 2009;8:526–533. doi:10.1038/nmat2444
   PubMed Web of Science ®Google Scholar
• Wu Y, Navarro F, Lal A, et al. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe. 2009;5:84–94.
   PubMed Web of Science ®Google Scholar
• Zamani M, Prabhakaran MP, Ramakrishna S. Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int J Nanomedicine. 2013;8:2997–3017. doi:10.2147/IJN.S43575
   PubMed Web of Science ®Google Scholar
• Krogstad EA, Woodrow KA. Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. Int J Pharm. 2014;475:282–291. doi:10.1016/j.ijpharm.2014.08.039
   PubMed Web of Science ®Google Scholar
• Chaowanachan T, Krogstad E, Ball C, Woodrow KA. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One. 2013;8:e61416. doi:10.1371/journal.pone.0061416
   PubMed Web of Science ®Google Scholar
• Carson D, Jiang Y, Woodrow KA. Tunable release of multiclass anti-HIV drugs that are water-soluble and loaded at high drug content in polyester blended electrospun fibers. Pharm Res. 2016;33:125–136. doi:10.1007/s11095-015-1769-0
   PubMed Web of Science ®Google Scholar
• Blakney AK, Krogstad EA, Jiang YH, Woodrow KA. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int J Nanomedicine. 2014;9:2967–2978. doi:10.2147/IJN.S61664
   PubMed Web of Science ®Google Scholar
• Ball C, Woodrow KA. Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV. Antimicrob Agents Chemother. 2014;58:4855–4865. doi:10.1128/AAC.02564-14
   PubMed Web of Science ®Google Scholar
• Ball C, Chou SF, Jiang Y, Woodrow KA. Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc. Mater Sci Eng C Mater Biol Appl. 2016;63:117–124. doi:10.1016/j.msec.2016.02.018
   PubMed Web of Science ®Google Scholar
• Zhang T, Sturgis TF, Youan -B-B. Ph-Responsive Nanoparticles Releasing Tenofovir Intended for the Prevention of HIV Transmission Eur J Pharm Biopharm. 2011;79:526–536.
   PubMed Web of Science ®Google Scholar
• Machado A, Cunha-Reis C, Araújo F, et al. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery System Acta Biomaterialia. 2016;44:332–340.
   PubMed Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J Controlled Release. 2014;190:500–514. doi:10.1016/j.jconrel.2014.04.033
   PubMed Web of Science ®Google Scholar
• Ensign LM, Tang BC, Wang -Y-Y, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4:138ra179–138ra179.
   Google Scholar
• Ensign LM, Tang BC, Wang -Y-Y, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4. doi:10.1126/scitranslmed.3003453.
   PubMedGoogle Scholar
• Das Neves J, Araújo F, Andrade F, Amiji M, Bahia MF, Sarmento B. Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm Res. 2014;31:1834–1845.
   PubMed Web of Science ®Google Scholar
• Hua D, Liu Z, Wang F, et al. pH responsive polyurethane (core) and cellulose acetate phthalate (shell) electrospun fibers for intravaginal drug delivery. Carbohydr Polym. 2016;151:1240–1244. doi:10.1016/j.carbpol.2016.06.066
   PubMed Web of Science ®Google Scholar
• Tyo KM, Lasnik AB, Zhang L, et al. Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections. J Controlled Release. 2020;321:84–99.
   PubMedGoogle Scholar
• Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41:2545–2561. doi:10.1039/c2cs15327k
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329–347.
   PubMed Web of Science ®Google Scholar
• GeunHyung K, Hyeon Y, YunKyung P. Drug release from various thicknesses of layered mats consisting of electrospun polycaprolactone and polyethylene oxide micro/nanofibers. Appl Phys a Mater Sci Process. 2010;100:1197–1204. doi:10.1007/s00339-010-5785-y
   Google Scholar
• Wang Y-F, Guo H-F, Ying D-J. Multilayer scaffold of electrospun PLA-PCL-collagen nanofibers as a dural substitute. J Biomed Mater Res B Appl Biomater. 2013;101:1359–1366. doi:10.1002/jbm.b.32953
   PubMed Web of Science ®Google Scholar
• Liu L, Kamei K, Yoshioka M, et al. Nano-on-micro fibrous extracellular matrices for scalable expansion of human ES/iPS cells. Biomaterials. 2017;124:47–54.
   PubMedGoogle Scholar
• Okuda T, Tominaga K, Kidoaki S. Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J Controlled Release. 2010;143:258–264.
   PubMed Web of Science ®Google Scholar
• Vakilian S, Mashayekhan S, Shabani I, Khorashadizadeh M, Fallah A, Soleimani M. Structural stability and sustained release of protein from a multilayer nanofiber/nanoparticle composite. Int J Biol Macromol. 2015;75:248–257.
   PubMed Web of Science ®Google Scholar
• Kidoaki S, Kwon IK, Matsuda T. Mesoscopic spatial designs of nano- and microfiber meshes for tissue-engineering matrix and scaffold based on newly devised multilayering and mixing electrospinning techniques. Biomaterials. 2005;26:37–46.
   PubMed Web of Science ®Google Scholar
• Westling K, Pettersson K, Kaldma A, Navér L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS. 2012;26:714–717.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Houdaihed L, Evans JC, Allen C. Codelivery of paclitaxel and everolimus at the optimal synergistic ratio: a promising solution for the treatment of breast cancer. Mol Pharm. 2018;15:3672–3681.
   PubMedGoogle Scholar
• Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.
   PubMedGoogle Scholar
• Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS. 2011;25:1585–1594.
   PubMedGoogle Scholar
• Yang H, Li J, Patel SK, Palmer KE, Devlin B, Rohan LC. Design of poly (lactic-co-glycolic acid)(PLGA) nanoparticles for vaginal co-delivery of griffithsin and dapivirine and their synergistic effect for HIV prophylaxis. Pharmaceutics. 2019;11:184.
   PubMed Web of Science ®Google Scholar
• Date AA, Shibata A, Goede M, et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+ efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res. 2012;96:430–436.
   PubMed Web of Science ®Google Scholar
• Chen BA, Panther L, Marzinke MA, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: a double-blind randomized trial. J Acquir Immune Defic Syndr. 2015;70:242.
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Palmer P, Scieux C, Molina J. Ninety-six—week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and Wild-Type Hepatitis B Virus. Clin Infect Dis. 2004;39:1062–1064.
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. The Lancet. 2009;374:796–806.
   PubMed Web of Science ®Google Scholar
• Dezzutti CS, Shetler C, Mahalingam A, et al. Safety and efficacy of tenofovir/IQP-0528 combination gels–a dual compartment microbicide for HIV-1 prevention. Antiviral Res. 2012;96:221–225.
   PubMed Web of Science ®Google Scholar
• Steinbach JM, Weller CE, Booth CJ, Saltzman WM. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Controlled Release. 2012;162:102–110. doi:10.1016/j.jconrel.2012.06.008
   PubMed Web of Science ®Google Scholar
• Pagels RF, Prud’Homme RK. Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics. J Controlled Release. 2015;219:519–535.
   PubMed Web of Science ®Google Scholar
• Shailender J, Ravi PR, Saha P, Dalvi A, Myneni S. Tenofovir disoproxil fumarate loaded PLGA nanoparticles for enhanced oral absorption: effect of experimental variables and in vitro, ex vivo and in vivo evaluation. Colloids Surf B Biointerfaces. 2017;158:610–619.
   PubMed Web of Science ®Google Scholar
• Das Neves J, Sarmento B. Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides. Acta Biomater. 2015;18:77–87.
   PubMed Web of Science ®Google Scholar
• Jäger A, Jäger E, Giacomelli FC, et al. Structural changes on polymeric nanoparticles induced by hydrophobic drug entrapment. Colloids Surf a Physicochem Eng Asp. 2018;538:238–249.
   Google Scholar
• Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336:367–375.
   PubMed Web of Science ®Google Scholar
• Fletcher P, Harman S, Azijn H, et al. Inhibition of HIV-1 infection by the candidate microbicide, dapivirine, a non-nucleoside reverse transcriptase inhibitor. Antimicrob Agents Ch. 2008.
   Google Scholar
• Tomoda K, Terashima H, Suzuki K, Inagi T, Terada H, Makino K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf B Biointerfaces. 2011;88:706–710.
   PubMed Web of Science ®Google Scholar